Louise Bergeron

University of Calgary — Canada

Biochemistry, Genetics and Molecular Biology · Life Sciences

16h-index3.6kcitations26works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Degradation and Inhibitors(5), Systemic Lupus Erythematosus Research(4), Multiple Myeloma Research and Treatments(4), Epigenetics and DNA Methylation(3), Cell death mechanisms and regulation(3)

Publications26 total

Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus
The Journal of Rheumatology·2018· 61 citedOpen Access
CS-36 Recommendations for the assessment of systemic lupus erythematosus in canada
2018· 1 citedOpen Access
Identification of potent, selective KDM5 inhibitors
Bioorganic & Medicinal Chemistry Letters·2016· 44 citedOpen Access
Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials
Journal of Medicinal Chemistry·2016· 214 citedOpen Access
Corrigendum to “Development of methyl isoxazoleazepines as inhibitors of BET” [Bioorg. Med. Chem. Lett. 25/9 (2015) 1842–1848]
Bioorganic & Medicinal Chemistry Letters·2015· 1 cited
Development of methyl isoxazoleazepines as inhibitors of BET
Bioorganic & Medicinal Chemistry Letters·2015· 22 cited
Systemic Autoimmune Rheumatic Disease Prevalence in Canada: Updated Analyses Across 7 Provinces
The Journal of Rheumatology·2014· 41 citedOpen Access
Discovery and Optimization of Tetramethylpiperidinyl Benzamides as Inhibitors of EZH2
ACS Medicinal Chemistry Letters·2014· 63 citedOpen Access
Rheumatoid arthritis prevalence in Quebec
BMC Research Notes·2014· 29 citedOpen Access
Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth
Chemistry & Biology·2013· 154 cited
Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors
ACS Medicinal Chemistry Letters·2013· 103 citedOpen Access
Trauma Associated with Perinatal Events: Birth Experience, Prematurity, and Childbearing Loss
2013· 4 cited
Abstract B179: Mechanism of antitumor activity of BET inhibitors in models of lymphomas and leukemia.
Molecular Cancer Therapeutics·2011
Targeting MYC dependence in cancer by inhibiting BET bromodomains
Proceedings of the National Academy of Sciences·2011· 1.1k citedOpen Access
A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHR
Cancer Cell·2002· 427 citedOpen Access
Sealing one's fate: control of cell death in neurons
Current Opinion in Neurobiology·1998· 57 cited
Activation of Caspase-2 in Apoptosis
Journal of Biological Chemistry·1997· 178 citedOpen Access
Specific Cleavage of α-Fodrin during Fas- and Tumor Necrosis Factor-induced Apoptosis Is Mediated by an Interleukin-1β-converting Enzyme/Ced-3 Protease Distinct from the Poly(ADP-ribose) Polymerase Protease
Journal of Biological Chemistry·1996· 211 citedOpen Access
Effects of Human Immunodeficiency Virus Type 1 Infection on Programmed Cell Death in the Presence or Absence of Bcl-2
Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology·1996· 16 cited
Ich-1, an Ice/ced-3-related gene, encodes both positive and negative regulators of programmed cell death
Cell·1994· 837 cited
page 1 of 2Next →

Frequent Co-authors

Péter Sandy(8), James E. Audia(7), Jennifer A. Mertz(6), Robert J. Sims(6), Brian K. Albrecht(6), Christopher G. Nasveschuk(6), Jean-Christophe Harmange(6), Barbara M. Bryant(5), Victor Gehling(5), Yves Leblanc(5), Florence Poy(5), Srividya Balasubramanian(4), Michael C. Hewitt(4), Rishi G. Vaswani(4), Alexandre Côté(4), S.F. Bellon(4), Richard Cummings(4), Hariharan Jayaram(4), Shivangi Joshi(4), Eneida Pardo(4)